Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0242


Triple-negative breast cancer: From microarrays basal-like subtype to NGS molecular classification and new drugs development .

Peter M. Schlag, MD.

Affiliation: Charité-Universitätsmedizin Berlin, Campus Mitte, Klinik für Allgemein-Visceral-, Gefäss- und Thoraxchirurgie, Charitéplatz 1, 10117, Berlin, Germany.

E-mail :

Approximately 10-20% of breast cancers don't express hormones (estrogen receptor [ER], progesterone receptor [PR]) or human epidermal growth factor receptor type 2 (HER2) proteins termed as triple-negative breast cancer (TNBC). This is an aggressive heterogeneous tumor with poor prognosis and highly resistant to chemotherapy that is currently the only available treatment along with surgery and radiotherapy. Despite research advances with the microarrays-based definition of basal-like subtype and PA RP drugs neither taxonomy nor signaling pathway have been established as standard approaches to diagnose and predict therapeutic response while no effective targeted drug has been discovered. Here I discuss the biomedical research progress but also the limitations in clinical practice to manage this difficult-to-treat disease. Moreover, the future perspectives of next-generation sequencing technologies for genomic, transcriptomic and genomic analysis promising the next-generation drugs and biomarkers are also summarized.

(Citation: Gastric & Breast Cancer 2012; 11(3): 135-139)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 10 July 2012